Key result
New oral anticoagulants, including direct thrombin and Xa inhibitors, offer promising alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation despite potential limitations.
Why the study?
Do new oral anticoagulants prevent stroke compared to vitamin K antagonists in patients with atrial fibrillation?
Do new oral anticoagulants prevent stroke compared to vitamin K antagonists in patients with atrial fibrillation?
This review highlights that while new oral anticoagulants offer alternatives to warfarin for stroke prevention in atrial fibrillation, the perceived drawbacks of warfarin may sometimes be clinical assets, requiring individualized patient management.
Answers are grounded in this paper and cite their sources.
May support individualized anticoagulant selection in atrial fibrillation; leaves open definitive comparisons versus optimized vitamin K antagonists.
Stroke prevention in atrial fibrillation (AF) is a rapidly expanding indication for lifelong oral anticoagulation. The vitamin K antagonists (VKAs) effectively prevent stroke, but are notoriously difficult to manage and are associated with frequent adverse events. These factors account for the widespread underuse of warfarin for patients with AF who are qualified candidates for therapy. New oral anticoagulants with different mechanisms of action are beginning to exit phase III trials and may replace the VKAs for a number of indications, especially AF. The oral direct thrombin and Xa inhibitors are furthest along in development. Dabigatran etexilate, a thrombin inhibitor, has recently shown excellent outcomes in the prevention of stroke in patients with AF. The oral Xa inhibitors are still in phase III trials for stroke prevention in AF, but results from trials for other indications look promising. These short-acting, short-duration, unmonitored drugs are not without limitations and potential adverse effects. The perceived drawbacks of the VKAs may actually be assets in the management of patients with AF, and the pros and cons of each class of drug must be taken into account as physicians consider or patients request transition to a new class of oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Jack Ansell (2010) conducted a review in Atrial fibrillation. New oral anticoagulants (direct thrombin and Xa inhibitors) vs. Vitamin K antagonists (Warfarin) was evaluated. New oral anticoagulants, including direct thrombin and Xa inhibitors, offer promising alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation despite potential limitations.
Synapse has enriched 10 related papers. Consider them for comparative context: